Affimed N.V. AFMDQ
Set alert
0.00 USD 0.00 0.00%
At close · Oct 30
0.0001 Day range 0.0001
0.00001 52-week range 0.05
- YTD
- +2,900.00%
- 1 year
- +2,900.00%
- Open
- 0.0001
- Prev close
- 0.003
- Mkt cap
- 49.18K
- Vol
- 2.60K
- Avg vol
- 12.05K
- EPS
- -74.66
- P/E
- 0.00
More statistics
- Low
- 0.0001
- High
- 0.0001
3M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 6 days ago |
| RSI: Overbought | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 2, 2026 | 1 month ago |
| RSI: Overbought | Oct 2, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
Financials — quick view
AFMDQ Revenue — quarterly 155.00K
AFMDQ Net income — quarterly -15.14M
AFMDQ EPS — quarterly -0.94
News
- Affimed Announces Receipt of Nasdaq Delisting Notice
- Affimed Announces Filing for the Opening of Insolvency Proceedings
- Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
- Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
- Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
- Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
- Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
- Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
- Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
Your note
Sign in to keep a note on AFMDQ — it syncs with the Stock Master app.